The attack happened on a pedestrian shopping street
The attack happened on a pedestrian shopping street
‘If the prime minister had any judgment, he would have sacked the secretary of state,’ shadow schools minister says
Silva netted the crucial late opener and Gundogan scored a penalty in a tremendously eventful fixture
Former president made almost 21 untrue statements a day while in office, analysis suggests
Biden and Harris dress to reassure that normal service is restoredThe optics of this inauguration were serene, respectful and quietly joyous, with US designers centre stage• Joe Biden’s inauguration – live updates
Bengaluru (Karnataka) [India], January 21 (ANI): In a major boost to the Bharatiya Janata Party (BJP) government in the State, the Karnataka High Court on Wednesday observed that the provision in the ordinance relating to ban on cow slaughter is constitutionally valid.
Holidaymakers in 2021 must be fully vaccinated against Covid-19, the travel firm says.
Silva and Gündogan send Manchester City top as Aston Villa rue luck
Man United are aiming to retake top spot in the Premier League as they travel to west London to face Fulham this evening. Leicester City beat Chelsea to go top on Tuesday, but Man City then took first place with a win over Aston Villa before United’s game in the capital tonight. As for Fulham, Scott Parker’s side have looked more impressive of late after a poor start to the season, but they are struggling to turn draws into wins as they sit four points away from safety - albeit with games in hand over fellow strugglers Brighton and Newcastle.
Country singer performed ‘Amazing Grace’ as Biden was sworn in as president
Inauguration milestone begins a vice presidency unlike any other
Consultation launches over suggested plan for grading
NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Hennessy Capital Investment Corp. V (NASDAQ: HCICU) (the “Company”) announced today that it closed its upsized initial public offering of 34,500,000 units, including 4,500,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per unit, resulting in gross proceeds of $345,000,000. The units are listed on The Nasdaq Capital Market (“Nasdaq”) and commenced trading under the ticker symbol “HCICU” on January 15, 2021. Each unit consists of one share of the Company’s Class A common stock and one-fourth of one redeemable warrant, each whole warrant enabling the holder thereof to purchase one share of Class A common stock at a price of $11.50 per share. Only whole warrants are exercisable. Once the securities comprising the units begin separate trading, the Class A common stock and warrants are expected to be listed on Nasdaq under the symbols “HCIC” and “HCICW,” respectively. The Company is a blank check company founded by Daniel J. Hennessy and formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business, industry, sector or geographical location, it intends to focus its search on target businesses in the sustainable industrial technology and infrastructure industries. Citigroup Global Markets Inc. and Barclays Capital Inc. served as joint book-running managers for the offering and Roth Capital Partners, LLC and Loop Capital Markets LLC served as co-managers for the offering. Of the proceeds received upon the consummation of the offering and simultaneous private placements of warrants, $345,000,000 (or $10.00 per unit sold in the offering) was placed in the Company’s trust account. An audited balance sheet of the Company as of January 20, 2021 reflecting receipt of the proceeds upon consummation of the offering and the private placement will be included as an exhibit to a Current Report on Form 8-K to be filed by the Company with the Securities and Exchange Commission (“SEC”). The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 1-800-831-9146; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at 888-603-5847, or by email at Barclaysprospectus@broadridge.com. Registration statements relating to these securities have been filed with the SEC and were declared effective on January 14, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. FORWARD-LOOKING STATEMENTS This press release contains statements that constitute “forward-looking statements,” including with respect to the initial public offering and the search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s final prospectus for the offering filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact CODY SLACHGateway IRP: (949) 574-3860E: HCIC@Gatewayir.com
Collier’s Medical Equipment, which serves nearly every major healthcare system in the Carolinas, will offer HealthySole UVC light units.
LEAD PLAINTIFF DEADLINE IS MARCH 16, 2021NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces the filing of a federal securities class action lawsuit in the United States District Court for the Central District of California against Decision Diagnostics Corp. (“Decision Diagnostics” or “the Company”) (OTCBB: DECN) on behalf of investors who purchased the Company's securities between March 3, 2020 and December 17, 2020, inclusive (the ''Class Period'') All investors who purchased shares of Decision Diagnostics Corp. and incurred losses are urged to contact the firm immediately at email@example.com or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or join the case on our website, www.whafh.com. If you have incurred losses in the shares of Decision Diagnostics Corp., you may, no later than March 16, 2021, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as an investor in the shares of Decision Diagnostics Corp. CLICK HERE TO JOIN CASE According to the filed Complaint, the Company made false and misleading statements to the market. Decision Diagnostics failed to develop a viable COVID-19 test in any form, let alone a test that could detect the virus in less than one minute. The Company was not capable of meeting the U.S. Food and Drug Administration’s (FDA's) EUA testing requirements for its purported COVID-19 test. Despite this inability to meet FDA requirements, the Company touted an unrealistic time to market for its tests. Based on these facts, the Company’s public statements were false and materially misleading throughout the class. Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas, and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation. If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at firstname.lastname@example.org, or visit our website at www.whafh.com. Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq.Gregory Stone, Director of Case and Financial AnalysisEmail: email@example.com, firstname.lastname@example.org or email@example.comTel: (800) 575-0735 or (212) 545-4774 This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
As the 46th president was speaking, conspiracies began to crumble under the weight of reality as QAnon realized that Trump is no god
Bernardo Silva and Ilkay Gundogan finally ended Aston Villa’s resistance to send Manchester City to the top of the Premier League, before Manchester United visited Fulham. In an enthralling end-to-end game, City and their visitors created, and spurned, chance after chance until a rocket from Bernardo and a penalty by Gundogan settled matters late on. The game started to frantic fashion and Bernardo was denied what looked a certain opener after just four minutes, but his effort from two yards out was denied by Emi Martinez.
JD Wetherspoon doesn't need any more beer money from SunakWhile smaller pubs ‘hang by a thread’, big chains amass war chests to capitalise on likelihood of those threads breaking
Follow all the latest updates from the game at Craven Cottage
Emergency Eyewash and Showers Market by End-user, Type, and Geography - Forecast and Analysis 2021-2025 is now available at Technavio
ROSELAND, N.J., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provides virtually painless and precise injections, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent relating to the disposable component of Milestone’s CompuFlo® Instrument. Dr. Mark Hochman, D.D.S., Inventor and Clinical Director for Milestone Scientific, commented, "Our clinical objectives have always been to focus on creating greater control and safety of our disposables. This aligns with our commercial strategy to ensure our disposables are protected due to the high margin, recurring revenue nature of these sales. This patent will cover the unique interactions of the disposable assembly and a micro-chip security verification feature embedded in the disposables, which provides numerous clinical and safety benefits for the patient and practitioner. This patent also covers the use of an embedded security chip, which is intended to enhance the safety and integrity of our system by preventing improper reuse of the disposables, as well as ensuring our instrument can only be used with authenticated disposables for the current and future systems. Ensuring the use of only authorized disposable components is critical to CompuFlo’s performance, safety as well as our long-term financial success of the Company. I am proud to state that we currently hold more than 20 patents surrounding our injection and drug delivery systems, which further solidifies our leadership position in this market.” About Milestone Scientific Inc. Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs and develops innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com. Safe Harbor Statement This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2019. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason. Contact:David Waldman or Natalya RudmanCrescendo Communications, LLCEmail: firstname.lastname@example.orgTel: 212-671-1020